Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes 11 RNAi-Related Patent Applications

Title: Short Interfering RNA Analogs
Number: 20070191294
Filed: March 22, 2004 PCT Filed: March 22, 2004
Lead Inventor: Joacim Elmen, Santaris Pharma
The invention, the patent application’s abstract states, “is directed to novel double-stranded short interfering analogues comprising locked nucleic acid monomers. Such compounds induce sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference. The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the … invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid monomer.”

Title: Gene Silencing by Systemic RNA Interference
Number: 20070191295
Filed: May 5, 2004 PCT Filed: May 5, 2004
Lead Inventor: Craig Hunter, Harvard University
The patent application, its abstract states, claims “nucleic acid and protein sequences relating to a gene required for systemic RNAi. … The SID-1 and 2 proteins are shown to be required for systemic RNAi. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the sid-1 and sid-2 genes and proteins are disclosed. Also provided are methods for reducing the expression of a target gene in a cell, a population of cells, or an animal.”

Title: Methods for Modulating IKK-Alpha Activity
Number: 20070191300
Filed: April 26, 2007
Lead Inventor: Jun Li, Boehringer Ingelheim
The patent application, according to its abstract, claims “a method for modulating NF-kappa-B- dependent gene transcription in a cell comprised of modulating IKK-alpha protein activity in the cell. The … invention also provides siRNA compositions and methods thereof for modulating NF-kappa-B-dependent gene transcription.”

Title: Induction of Apoptosis by Inhibition of Sirtuin SIRT1 Expression
Number: 20070197459
Filed: Feb. 11, 2005 PCT Filed: Feb. 11, 2005
Inventor: Jo Anne Milner, University of York
“The invention relates to the induction of apoptosis by inhibition of the sirtuin SIRT1 expression, in particular the induction of apoptosis in tumor cells,” the patent application’s abstract states. “Materials and methods for inhibiting SIRT1 expression are provided, including RNA interference methods. In particular, the invention provides a method of treating a proliferative disease comprising administering to an individual in need thereof an effective amount of a SIRT1 inhibitor.”

Title: RNAi Inhibition of Influenza Virus Replication
Number: 20070197460
Filed: Nov. 1, 2006
Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals
According to the patent application’s abstract, “the invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the down-regulation of influenza viral genes by chemically modified oligonucleotides.”

Title: Methods for Producing Hybrid Seed
Number: 20070199095
Filed: Sept. 20, 2006
Lead Inventor: Edwards Allen, Monsanto
“This invention provides methods for producing a non-natural hybrid seed,” the patent application’s abstract states. “Also disclosed are specific miRNAs and miRNA recognition sites useful for conferring inducible sterility on a crop plant, and recombinant DNA constructs, including such exogenous miRNA recognition sites.”

Title: Promoters for RNA Interference
Number: 20070202082
Filed: Nov. 7, 2006
Lead Inventor: Dong-Yan Jin, University of Hong Kong
The invention, the patent application’s abstract states, “provides vector systems based on the promoters of Epstein-Barr virus-encoded small RNAs that can be used to express and deliver desired RNA molecules such as small hairpin RNAs in mammalian cells. Such small hairpin RNAs are useful for RNA interference.”

Title: Methods for Gene Function Analysis
Number: 20070202505
Filed: Sept. 8, 2003
Lead Inventor: Alex Chenchik, System Biosciences
The invention “provides methods for analysis of gene function using effector libraries,” the patent application’s abstract states.
This method, according to the application, includes “obtaining at least two sets of defined nucleic acid sequences wherein each set comprises at least 100 effector nucleic acid sequences, and wherein one set of the nucleic acid sequences is arrayed on a microarray; cloning another set of nucleic acid sequences into a viral expression vector to produce effector constructs; packaging the effector constructs into viral particles to produce a viral effector library; [and] transducing target cells with the viral effector library.” The method further includes “assaying the target cells for a phenotype of interest; selecting one or more target cells with the phenotype of interest; isolating effector nucleic acids from the target cells with the phenotype of interest; [and] identifying one or more effector sequences present in the target cells with the phenotype of interest by hybridization of the isolated effector nucleic acids to the microarray.”

Title: RNAi Agents for Anti-SARS Coronavirus Therapy
Number: 20070203082
Filed: April 26, 2004 PCT Filed: April 26, 2004
Lead Inventor: Quinn Tang, Intradigm
According to the patent application’s abstract, the invention comprises “compositions and methods that are useful for the treatment of severe acute respiratory syndrome. More specifically, nucleic acid agents such as siRNA molecules and their analogues that target respiratory infections including SARS coronavirus and their methods of use are described, for clinical treatments of SARS, respiratory viral infections, for prevention and treatment of respiratory infections as needed for bio-defense, for treatment of respiratory diseases, and for discovery of therapeutic targets for respiratory diseases and infections.”

Title: Interfering RNA Duplex Having Blunt Ends and 3’ Modifications
Number: 20070203084
Filed: Aug. 27, 2004 PCT Filed: Aug. 27, 2004
Lead Inventor: Jan Weiler, Novartis
The invention “relates to double-stranded RNA compounds with at least one blunt end comprising at least one 3'-end [modification] … and wherein said double-stranded RNA mediates RNA interference. Preferred 3'end modifications are: phosphate, phosphorothioate, abasic ribonucleoside, hydroxyphopyl phosphodiester.”

Title: Adenosine Therapy Via Interfering RNA
Number: 20070203086
Filed: Feb. 24, 2006
Inventor: Detlev Boison, Legacy Research
The invention, according to the patent application’s abstract, comprises a “system, including methods and compositions, for treating medical conditions via adenosine therapy with interfering RNA that selectively inhibits adenosine metabolism.”

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.